Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more
Shandong Sinobioway Biomedicine Co Ltd (002581) - Total Assets
Latest total assets as of September 2025: CN¥2.21 Billion CNY
Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) holds total assets worth CN¥2.21 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Sinobioway Biomedicine Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Sinobioway Biomedicine Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Sinobioway Biomedicine Co Ltd's total assets of CN¥2.21 Billion consist of 34.0% current assets and 66.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.1% |
| Accounts Receivable | CN¥144.53 Million | 6.6% |
| Inventory | CN¥79.64 Million | 3.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥93.47 Million | 4.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Sinobioway Biomedicine Co Ltd's current assets represent 34.0% of total assets in 2024, a decrease from 58.9% in 2007.
- Cash Position: Cash and equivalents constituted 23.1% of total assets in 2024, up from 20.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Shandong Sinobioway Biomedicine Co Ltd Competitors by Total Assets
Key competitors of Shandong Sinobioway Biomedicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Shandong Sinobioway Biomedicine Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shandong Sinobioway Biomedicine Co Ltd generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shandong Sinobioway Biomedicine Co Ltd is currently not profitable relative to its asset base.
Shandong Sinobioway Biomedicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.20 | 11.18 | 3.70 |
| Quick Ratio | 3.52 | 9.93 | 3.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥597.91 Million | CN¥ 657.33 Million | CN¥ 559.30 Million |
Shandong Sinobioway Biomedicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Sinobioway Biomedicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.58 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | CN¥2.20 Billion |
| Market Capitalization | $529.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Sinobioway Biomedicine Co Ltd's assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Sinobioway Biomedicine Co Ltd's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below shows the annual total assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.20 Billion | -6.04% |
| 2023-12-31 | CN¥2.34 Billion | -18.22% |
| 2022-12-31 | CN¥2.86 Billion | +3.69% |
| 2021-12-31 | CN¥2.76 Billion | +12.72% |
| 2020-12-31 | CN¥2.44 Billion | -28.38% |
| 2019-12-31 | CN¥3.41 Billion | -20.48% |
| 2018-12-31 | CN¥4.29 Billion | +7.41% |
| 2017-12-31 | CN¥4.00 Billion | +48.73% |
| 2016-12-31 | CN¥2.69 Billion | +11.25% |
| 2015-12-31 | CN¥2.42 Billion | +213.95% |
| 2014-12-31 | CN¥769.49 Million | -0.56% |
| 2013-12-31 | CN¥773.80 Million | +6.14% |
| 2012-12-31 | CN¥729.02 Million | +5.63% |
| 2011-12-31 | CN¥690.19 Million | +229.16% |
| 2010-12-31 | CN¥209.68 Million | +27.12% |
| 2009-12-31 | CN¥164.95 Million | +14.92% |
| 2008-12-31 | CN¥143.53 Million | +50.23% |
| 2007-12-31 | CN¥95.54 Million | -- |